Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout ...

It’s the hot-shot fix that took Hollywood — and now high school — by storm. Ozempic and other so-called “miracle” weight-loss ...

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

THURSDAY, June 5, 2025 (HealthDay News) — More American teenagers now use the weight-loss drug Wegovy, as doctors and ...

American teens are increasingly turning to the weight-loss drug Wegovy as more families and their doctors gain confidence in ...

Despite the jump in the number of teens being prescribed Wegovy, it still represents only a small fraction of kids who are living with obesity. Approximately one in 5 children and teens in the U.S.

Since the FDA said shortages of Wegovy and Zepbound are over, compounding pharmacies are supposed to stop making copies of the drugs. But some of those business are trying to find ways to continue.

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

Common GLP-1 weight loss drugs - including Wegovy and Ozempic - may not work for everyone in a “real-world” setting, ...

GLP-1 weight loss drugs, such as Wegovy and Zepbound, have helped millions of people shed weight and curb food cravings. But they create additional health problems, Kessler says, and there's not ...

The New Science of Achieving a Healthy Weight” (Flatiron Books), former FDA Commissioner David A. Kessler argues that ultraprocessed foods — meaning ...